Zhengye Biotechnology-AZYBT
13F holders, Q4 2025 (December 31)11holders +1
2new positions
1sold out
1famous investor
$1.15avg. 13F price*
At the end of Q4 2025, 11 institutions reported holding Zhengye Biotechnology-A (ZYBT) in their 13F filings, up 1 from Q3 2025. 2 opened new positions and 1 sold out. The largest holders were WINTON GROUP Ltd ($73K), XTX Topco Ltd ($68K) and Invesco Ltd. ($40K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Zhengye Biotechnology-A
- CUSIP
- G989MS101
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $526 |
| Exits | 1 | $38K |
All 13F filers, Q3 2025 → Q4 2025: 90,964 shares bought and 19,022 shares sold, net +71,942 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| WINTON GROUP Ltd | 0.00% | Add +193.8% | 63,297 | $73K |
| XTX Topco Ltd | 0.00% | Add +71.4% | 59,286 | $68K |
| Invesco Ltd. | 0.00% | Reduce -4.8% | 34,688 | $40K |
| Citadel Advisors | 0.00% | Add +161.7% | 30,576 | $35K |
| Geode Capital Management, LLC | 0.00% | No change | 29,068 | $33K |
| UBS Group AG | 0.00% | Add +110.6% | 9,115 | $10K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -50.5% | 2,207 | $3K |
| Morgan Stanley | 0.00% | Reduce -20.0% | 1,607 | $2K |
| JPMorgan Chase & Co. | 0.00% | New | 457 | $526 |
| Caitong International Asset Management Co., Ltd | 0.00% | No change | 1 | $1 |
| Royal Bank of Canada | 0.00% | New | 383 | $0 |
"% of holder's portfolio" is ZYBT's weight in each manager's 13F, not the share of Zhengye Biotechnology-A the manager owns.